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Background: Radical prostatectomy is a standard surgical treatment of clinically localized prostate cancer. Margin
status has been found to be an independent predictor of biochemical recurrence (BCR) after open radical
prostatectomy in several large series but this is still controversy in Robotic Assisted Radical Prostatectomy (RARP)
series. We therefore wanted to investigate the prognostic significance of positive surgical margin (PSM) and other
pathological factors on BCR in patients treated with RARP by a single surgeon.
Methods: Prospectively collected data of 439 patients treated with RARP between October 2005 and June 2013 by
a single surgeon at a single institution were analyzed. BCR was defined as follow-up PSA level > 0.2 ng/ml on two
separate occasions or patients who had to undergo salvage therapy. Kaplan Meier curves and Log Rank test were
used to compare the risk of BCR. Univariate and Multivariate Cox Regression analyses were performed to determine
the prognostic impact of age, BMI, prostate weight, PSA prior to surgery, pathological T-stage, pathological Gleason
sum, PSM and operative period.
Results: In this study period, 34 out of 439 had BCR, giving an overall BCR rate of 7.7% for this cohort. Overall
2- and 3-year BCR-free survival rates were 93% and 88%, respectively. Patients with a PSM had a 2-year BCR free
survival of 88% compared to 94% in those with negative margins (p < .0001). On the multivariate analysis, PSM as
well as pathological Gleason sum > = 8, PSA, pathological stage and operative period were significantly associated
with BCR.
Conclusions: In our case series of RARP performed by a single surgeon, PSM as well as pathological Gleason sum,
PSA, pathological stage and early operative period for this surgeon were the independent predictors of BCR.
Keywords: Biochemical recurrence, Biochemical recurrence free survival, Cox regression analysis, Positive surgical
margin, Robotic assisted radical prostatectomyBackground
Radical retropubic prostatectomy (RRP) is a standard
surgical treatment of clinically localized prostate cancer.
Recently robotic-assisted radical prostatectomy (RARP)
also has become very popular in the United States and
Europe; it has been estimated that > 75% of radical pros-
tatectomies are performed using the da Vinci platform
(Intuitive Surgical, Inc., Sunnyvale, CA, USA) [1]. Sys-
tematic review of the literature revealed that RARP* Correspondence: tanimo10@gmail.com
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unless otherwise stated.represented a safe procedure with better perioperative
outcomes, such as reduced blood loss and postoperative
hospital stay, when compared with open surgery [2,3].
Moreover, recent meta-analysis showed similar positive
surgical margin (PSM) rates and biochemical recurrence
(BCR) free survival estimates when comparing RARP
with RRP and RARP with laparoscopic radical prostatec-
tomy (LRP) [3]. At our institution, RARP was adopted in
lieu of LRP in 2005 and our previous report also sup-
ported these findings [4].
Margin status is considered an independent predictor
of BCR after open radical prostatectomy in several largeral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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tectomy series [8-11]. However, in the largest reported
robotic series with a median follow-up of 36 months,
margin status was not shown to be an independent BCR
predictor [12].
The aim of this study was to assess the prognostic sig-
nificance of PSM and other pathological factors on BCR
in patients treated with RARP by a single surgeon.
Methods
A single institution retrospective review of RALP per-
formed by a single surgeon between October 2005 and
June 2013 was performed. This is a Thomas Jefferson
University Institutional Review Board approved data-
base (approval reference: 02.9000) in which data has
been collected prospectively. The written informed con-
sent for participation in the study was obtained from all
patients. Patients were initially evaluated at a multidiscip-
linary clinic. Of 1062 consecutive patients who underwent
RARP in our institution, a total of 561 patients were
treated by a single surgeon (EJT) during this time. Follow-
ing the exclusion of patients who did not have recorded
PSA values postoperatively (n = 73) or had adjuvant radi-
ation or hormonal treatment (n = 9), who had positive
lymph node (n = 2), pT3b (n = 2), pT3a with positive sur-
gical margin (n = 3), pT3a with tertiary GS 5 (n = 1) or
high GS (4 + 5) with positive surgical margin (n = 1), the
remaining 439 patients were evaluated in the present
study. None of these patients had been administered hor-
mones prior to surgery. All prostate specimens were sub-
mitted in their entirety and underwent standard whole
mount step sectioned pathologic analysis in order to de-
termine surgical Gleason score, pathological stage and
margin status. The location of each positive margin on the
prostatic specimen was examined. A confirmatory second
level pathologic review with a genitourinary pathologist
and the surgical team was performed weekly in a multidis-
ciplinary genitourinary pathology conference. BCR was
defined as follow-up PSA level > 0.2 ng/ml on two sep-
arate occasions or patients who had to undergo salvage
therapy. Kaplan Meier curves and Log Rank Test were
used to compare the risk of developing BCR. Univariate
and Multivariate Cox Regression analyses were per-
formed to determine the prognostic impact of patho-
logical factors including age, BMI at surgery, pre-operative
PSA (< 10 ng/ml versus > = 10 ng/ml), operative period
(early operative period for this surgeon, 2005 – 2007 and
later operative period 2008 – 2013), PSM, foci of PSM
(unifocal versus multifocal versus none), pathological
stage (T2 versus T3/4), pathological Gleason sum (<= 6
versus 7 versus > = 8), extracapsular extension (unifocal
versus multifocal versus none), seminal vesicle involve-
ment, perineural invasion, and prostate size as determined
by weight in grams.All procedures were performed by a single surgeon
(EJT) using the da Vinci® Surgical System. Laparoscopic
ports were placed using a 6-port transperitoneal ap-
proach. The seminal vesicles were approached poster-
iorly. Nerve sparing procedures were attempted for all
patients with appropriate preoperative potency and ac-
ceptable oncologic risk. For the initial 50 RARP patients,
obturator lymphadenectomy was performed if the pre-
operative Kattan nomogram [13] predicted greater than
1% risk of lymph node invasion. Subsequently, all pa-
tients were treated with obturator node dissection with
high risk patients, as determined by the D’Amico criteria
[14], receiving extended lymphadenectomy to include
external iliac nodes.
Statistical analysis
All statistical analyses were two-tailed. Differences were
considered significant if the p value was < 0.05. The stat-
istical analysis was conducted with JMP version 9.0 (SAS
Institute Inc, Cary, NC, USA).
Results
Out of 531 patients treated by a single surgeon, 439
were included in this study. The clinical and pathological
characteristics of the 439 patients are listed in Table 1.
Median patient age at prostatectomy was 59 years. Median
PSA was 4.9 ng/ml (interquartile range, (IQR) 3.9 – 6.3).
Overall, 422 patients (96%) underwent lymph node dissec-
tion with a median rate of 7 lymph nodes (IQR 4 – 12).
Among those, 4 patients (0.9%) had at least 1 positive
node. The median follow-up time was 16 months (IQR
6 – 34). In this study, 34 of the 439 follow-up patients
(7.7%) experienced BCR. Among those, 31 (91%) BCR
were due to elevated PSA recurrence and only 3 re-
ceived salvage radiation therapy before a documented
PSA increase. All 20 patients with secondary treatment
had salvage radiation therapy with or without hormo-
nal therapy. In all, 119 patients (27.1%) had PSM and
among those, 102 (85.7%) were unifocal. The locations
of PSM (Additional file 1: Table S1) were posterolateral
(54.6%), bladder neck / base (14.3%) and apex (10.9%).
The PSM rates were 20%, 49% and 50% in patients with
stage pT2, pT3a and pT3b respectively. Unfortunately,
we failed to identify improvements in the PSM over
time (Additional file 2: Table S2).
Overall 2-, and 3-year BCR-free survival (BCRFS) rates
were 93% and 88%, respectively (Figure 1a). Patients with
a PSM had a 2-year BCRFS of 88% compared to 94% in
those with negative margins (Figure 1b; p < 0.0001). The
two year BCR free rate was 99%, 94% and 58% for patients
with pathological Gleason sum < = 6, 7 and > = 8, respect-
ively (Figure 1c; p < 0.0001); the same rate was 98% and
73% in patients with pT2 disease and with pT3/4 respect-
ively (Figure 1d; p < 0.0001). Preoperative PSA > = 10
Table 1 Patient characteristics (n = 439)
BCR(+) n = 34 BCR(−) n = 405
Median IQR Median IQR Median IQR
Age (years) 59 55-65 62 56-66 59 55-64
BMI (kg/m2) 28.1 25.6-31.2 29.3 25.5-33.2 28 25.7-31.1
Preoperative PSA (ng/ml) 4.9 3.9-6.3 6.7 4.5-13.2 4.9 3.9-6.0
Follow up time (months) 16 6-34 33 3-49 15 6-33
n % BCR(+) n = 34 BCR(−) n = 405
Clinical Stage
T1c 342 77.9% 22 64.7% 320 79.0%
T2a 65 14.8% 5 14.7% 60 14.8%
T2b 24 5.5% 5 14.7% 19 4.7%
T2c 7 1.6% 2 5.9% 5 1.2%
T3a 1 0.2% 0 0.0% 1 0.2%
Clinical Gleason
≤6 216 49.2% 8 23.5% 208 51.4%
7 202 46.0% 21 61.8% 281 69.4%
≥8 21 4.8% 5 14.7% 16 4.0%
Pathological Stage
T2a 50 11.4% 0 0.0% 50 12.3%
T2b 7 1.6% 0 0.0% 7 1.7%
T2c 280 63.8% 10 29.4% 270 66.7%
T3a 75 17.1% 12 35.3% 63 15.6%
T3b 24 5.5% 9 26.5% 15 3.7%
T4 3 0.7% 3 8.8% 0 0.0%
Pathological Gleason
≤6 157 35.8% 0 0.0% 157 38.8%
7 241 54.9% 6 17.6% 235 58.0%
≥8 41 9.3% 28 82.4% 13 3.2%
Operative period
2005-2007 102 23.2% 14 41.2% 88 21.7%
2008-2010 203 46.2% 13 38.2% 190 46.9%
2011-2013 134 30.5% 4 11.8% 130 32.1%
Positive Surgical Margin 119 27.1% 20 58.8%
BCR 34 7.7% 34 100.0%
PSA > 0.2 31 7.1% 31 91.2%
SalvageXRT 20 4.6% 20 58.8%
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2005 – 2007 (Figure 1f; p = 0.0093), which was the
period during which the first RARPs were performed
by this surgeon, were also significantly associated with
increased risk of BCR.
Table 2 summarizes data of the univariate and multi-
variate analyses for predictors of BCR. On univariate
analysis, BMI, pathological Gleason sum > = 8, patho-
logical stage, PSM, the foci of PSM, PSA and operative
period were significantly related with BCR. Extracapsularextension (unifocal versus multifocal versus none), sem-
inal vesicle involvement and perineural invasion were also
related with BCR (p < 0.0001, p < 0.0001 and p = 0.0004,
respectively; data not shown). On multivariable analysis,
pathologic Gleason sum was the strongest predictor of
BCR, with an HR of 6.76 (p = 0.0030) for Gleason > = 8
when compared to Gleason < = 6. The presence of PSM
also represented independent predictors of BCR (HR 2.69;
p = 0.0153) as well as PSA, pathological stage (HR 4.48;
p = 0.0011) and early operative period (HR 0.38; p = 0.0113).
(-) 320 255 194 155 118 90 68 48 32 25 18 
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Figure 1 Kapalan-Meier curves. (a) overall, (b) Biochemical recurrence free survival (BCRFS) in patients with (red curve) and without positive
surgical margins (blue curve). (c) BCRFS for pathological Gleason < =6(red curve), =7(green curve) and > =8(blue curve). (d) BCRFS for pathological
stage pT2 (red curve), pT3-4 (blue curve). (e) BCRFS for preoperative PSA < 10 (red curve), preoperative PSA > =10. (f) BCRFS in patients operated
in 2005–2007 (red curve), in 2008 - 2010(green curve), in 2011–2013 (blue curve).
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Table 2 Univariate and multivariate analyses of factors affecting BCR
Univariate analysis Multivariate analysis
Risk ratio (95% CI) p-value Risk ratio (95% CI) p-value
Age 1.03 (0.98-1.09) 0.2279 0.98 (0.92-1.05) 0.6476
BMI 1.09 (1.02-1.17) 0.0158 0.97 (0.90-1.04) 0.3369
Prostate Weight (gm) 0.99 (0.96-1.01) 0.2851 -
PSM 4.12 (2.09-8.34) <0.0001 2.69 (1.21-6.14) 0.0153
PSM foci
None 1.00 -
Unifocal 3.49 (1.67-7.32) 0.0010 -
Multifocal 9.23 (2.96-24.34) 0.0005 -
Pathological Gleason
≤6 1.00 1.00
7 2.39 (0.86-8.42) 0.1001 1.78 (0.58-6.63) 0.3226
≥8 21.11 (7.71-73.90) <0.0001 6.76 (1.87-29.21) 0.0030
Preoperative PSA
<10 1.00 1.00
≥10 6.66 (3.18-13.28) <0.0001 2.53 (1.06-5.81) 0.0360
Pathological Stage
pT2 1.00 1.00
pT3-4 10.89 (5.33-23.98) <0.0001 4.48 (1.83-11.30) 0.0011
Operative period
Before 2007 1.00 1.00
After 2008 0.36 (0.18-0.72) 0.0045 0.38 (0.18-0.80) 0.0113
BMI; body mass index, PSM; positive surgical margin.
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In our case series of RARP performed by a single sur-
geon, positive surgical margin as well as pathological
Gleason sum, PSA, pathological stage and early opera-
tive period were the independent predictors of BCR.
Most RARP studies report short-term (< 12 months)
follow-up outcomes, though 4 large studies recently re-
ported BCR free survival (BCRFS) after RARP with a
follow-up of more than 5 years [10,15-17]. The largest
report of PSA outcomes in the RARP literature is from
Menon et al. [16], who reported an overall BRFS of
86.4% for 1384 patients with a median follow-up of
60.2 months. Actual 3-and 5-yr BCRFS were 90.6% and
86.6%, respectively. On the other hand, Suardi et al. and
Liss et al. reported 3- and 5-year BCRFS of 94%, 86% in
184 patients and 87.8%, 84.9% in 435 patients, respect-
ively. In our study, mean follow-up was only 22 months
and it is too early to define 5-year BCRFS, but the over-
all 2-year and 3-year BCRFS was 93% and 88%, respect-
ively, which was comparable to previous reports.
The overall PSM rate in this series is 27.1% with a rate
of 19.9% for pT2 tumors. This is comparable to other
contemporaneous RARP series whose PSM rates were
6.5 - 29.5% overall and 2.5 - 22.7% in patients with stagepT2 [8-11,16-26]. Regarding risk factors for BCR, all
four large studies referenced above agreed that the
pathological Gleason score was an independent factor,
but two of them did not find that the presence of posi-
tive margins was significant on multivariate analysis.
Menon et al. showed the significance of positive margin
on BCR, although their previous series with follow-up of
36 months did not [12]. The reason for this may be that
the actual BCR rate (2.4%) was too low to power the
statistical significance in this cohort. Sooriakumaran
et al. reported an RARP case series of 944 patients with
median follow-up of 6.3 years, which showed that PSM
status as well as preoperative PSA > 10, pathological
Gleason sum > = 4 + 3, pathological T3 disease and
lower surgeon case volume were all associated with in-
creased risk of BCR on multivariable analysis.
Shikanov et al. reported not only the presence of PSM
but also PSM length (> 3 mm) to be independently asso-
ciated with BCR. Interestingly, patients with negative
margins and those with a positive margin less than
1 mm had similar rates of biochemical recurrence [9].
This finding is in keeping with others and suggests PSM
> 3 mm and multifocal positivity were associated with
risk of BCR [27]. Moskovic et al. reported that high body
Tanimoto et al. BMC Urology  (2015) 15:27 Page 6 of 7mass index does not affect BCR following robotic
assisted laparoscopic prostatectomy when BMI was
stratified into 3 groups (> = 30, > = 25 and < 30, < 25), al-
though there was a trend toward increased recurrence in
the obese [28]. In the present study, higher BMI had
higher BCR on univariate analysis, but not on multivari-
ate analysis.
With regard to the effect of surgeon experience on
BCR, Zorn et al. [29] demonstrated that the risk of PSA
recurrence was quite stable over 700 cases when com-
pared with 3 groups (cases 1–300, 301–500, and 501–
700). Samadi et al. also assessed the effect of surgeon ex-
perience and technical modifications, which were cate-
gorized as initial, intermediate and current technique, on
oncological outcome after RARP. Pathological T2 mar-
gin rates decreased continuously during the initial tech-
nique period, followed by a transient worsening of
margin rates during the intermediate time period and a
subsequent decrease during the period when the current
technique was used, but no significant differences were
noted in BCR rate between these groups. In both stud-
ies, follow-up duration was relatively short, and BCR-
free survival analyses adjusted for covariates were not
provided. In the present study, we adjusted BCR-free
survival for the covariates including pathological factors
with Cox Regression analysis. The early operative period,
2005–2007, which encompassed the first 100 cases, had
a significantly higher rate of BCR compared to the late
period, but there was no difference between 2008 –
2010 and 2011 – 2013. This suggested the risk of BCR
was stable after 100 cases.
It is also important to remember that BCR does not
necessarily lead to clinical recurrence or cancer specific
mortality, and BCR without clinical progression might
reflect the recurrence of indolent prostate cancer or the
presence of benign prostatic tissue left behind after sur-
gery [30]. Hence, it is necessary to follow up our cohort
further and determine the impact of BCR on longer-
term oncologic outcome.
Our study has some limitations. Many of the patients
were from outside our geographic area and are followed
locally. The median follow-up in these patients was
16 months, and so these results must be considered
early. In addition, factors potentially correlating with
BCR, such as length of PSM were not included in this
analysis. The main strength of our study is that only pa-
tients treated by a single surgeon were selected for this
analysis which was adjusted for the operative periods
with the aim of decreasing the influence of surgeons’
techniques on their outcomes.
Conclusions
In our case series of RARP performed by a single sur-
geon, positive surgical margins as well as pathologicGleason sum, PSA, pathologic stage and early opera-
tive period were the independent predictors of BCR.
Further follow-up is necessary to determine how this
finding will translate into cancer-specific and overall
survival outcome.
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